FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/論文
研究ライブラリに戻る
PubMedPreclinical

T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.

Yan Jun, Shi Chunhua, Yang Guojun, Tian Ze, Torikai Hiroki, Sukhumalchandra Pariya, Peng Shaohua, Chang Edward, Cui Meng, Kerros Celine
Leukemia2025DOI: 10.1038/s41375-025-02652-0
cathepsin G signal peptideCG1

品質スコア

6/10

引用

0

対象

非人間

Peptide Contacts分析

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of cathepsin G signal peptide, CG1 in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: A solid contribution to cathepsin G signal peptide, CG1 research. Worth reading alongside other studies on the same compounds for a balanced picture.

主要な見解

The study demonstrates the safety and efficacy of CG1/A2-targeting chimeric antigen receptor (CAR) T cells in targeting HLA-A2-restricted, cathepsin G-derived signal peptide CG1 in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

制限事項

The study is preclinical and has not been tested in human subjects yet. The safety and efficacy of the CAR T cells need to be confirmed through clinical trials.

この研究をどのように解釈するか

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Animal model results do not automatically translate to humans. Different species metabolize peptides differently, and dosing does not scale linearly.

4

In vitro (cell culture) studies demonstrate biological mechanisms but cannot account for the complexity of whole-organism physiology.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts分析

Highlighting the potential of CG1/A2-targeting CAR T cells as a novel immunotherapy approach in myeloid malignancies.

cathepsin G signal peptideCG1

Novel CAR T Cells Targeting Cathepsin G Signal Peptide Show Promise in Leukemia Treatment

Published: May 16, 2026 | Source: Leukemia (2025) | Category: cathepsin G signal peptide, CG1

Overview

A recent study published in Leukemia reveals the potential of chimeric antigen receptor (CAR) T cells targeting a specific signal peptide derived from cathepsin G (CG), known as CG1. This research offers new hope for treating acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) by leveraging an innovative immunotherapy approach.

Study Background

Immunotherapies have revolutionized cancer treatment, but the development of effective targets in myeloid malignancies has been challenging. The study builds on previous research where a T cell receptor mimic antibody targeting CG1 was developed and shown to be safe and efficacious against AML and CML. This new work aims to extend these findings by engineering CAR T cells that can recognize and target the same HLA-A2-restricted signal peptide, CG1.

What the Research Found

Researchers engineered CAR T cells using a T cell receptor mimic (TCR-m) specific for CG1/A2 complexes. These modified CAR T cells demonstrated high affinity for both CG1/A2 monomers and leukemia cells expressing this complex. The study showed that these CAR T cells were effective in preclinical models of AML and CML, indicating their potential as a therapeutic tool against these diseases.

What This Means for Peptide Users

While the findings are promising, it is important to note that this research has only been conducted in preclinical settings. For peptide users, particularly those involved in immunotherapy development or clinical trials, the study highlights a new direction in targeting myeloid malignancies through specific signal peptides. However, further validation and clinical testing are necessary before these CAR T cells can be used in patient care.

Limitations and Caveats

The primary limitation of this research is its preclinical nature; no human subjects have been involved yet. Additionally, the study focuses on HLA-A2-restricted CG1/A2 complexes, which limits applicability to patients with this specific genetic marker. The safety and efficacy profiles in humans remain unknown until clinical trials are conducted.

How This Compares to Previous Research

This work builds upon earlier studies that established the feasibility of targeting CG1 using TCR-m antibodies. Unlike those previous efforts, however, this study introduces a novel approach by utilizing CAR T cells engineered with the same specificity. While both methods show promise in preclinical settings, the use of CAR T cells may offer advantages such as enhanced persistence and anti-tumor activity.

Our Analysis

PeptideVault views this research positively but emphasizes the need for caution due to its preliminary stage. The innovative approach of targeting a signal peptide with CAR T cells represents an exciting development in cancer immunotherapy, particularly for myeloid malignancies where effective targets have been scarce. However, rigorous clinical validation is essential before these findings can be translated into practical medical applications.

Key Takeaways

  • Novel Target: CG1/A2 complexes represent a promising new target for CAR T cell therapy.
  • Preclinical Success: The study demonstrates efficacy in preclinical models of AML and CML.
  • Clinical Validation Needed: Further research is required to confirm safety and effectiveness in human patients.

Original Source

Citation: Yan Jun, Shi Chunhua, Yang Guojun et al. (2025). T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.. Leukemia. DOI: 10.1038/s41375-025-02652-0

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成され、ペプチドコミュニティにとって複雑な見解を読みやすくしました。情報確認のために常に元の論文をご確認ください。 cathepsin G signal peptideについてもっと知るには、以下の 研究ガイド.

引用

Yan Jun, Shi Chunhua, Yang Guojun et al.. (2025). T cell receptor mimic CAR T cells targeting cathepsin G signal peptide.. Leukemia. https://doi.org/10.1038/s41375-025-02652-0

全文はPubMedで見ることができます

関連論文

さらに探索

この内容は教育目的のみで使用される査読済みの研究から派生しています。医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。